156 related articles for article (PubMed ID: 26265036)
21. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis.
Takeuchi M; Kobayashi T; Biss T; Kamali F; Vear SI; Ho RH; Bajolle F; Loriot MA; Shaw K; Carleton BC; Hamberg AK; Wadelius M; Hirono K; Taguchi M; Wakamiya T; Yanagimachi M; Hirai K; Itoh K; Brandão LR; Ito S
Pharmacogenomics J; 2020 Apr; 20(2):306-319. PubMed ID: 31673144
[TBL] [Abstract][Full Text] [Related]
22. Polymorphisms of CYP2C9, VKORC1, MDR1, APOE and UGT1A1 genes and the therapeutic warfarin dose in Brazilian patients with thrombosis: a prospective cohort study.
de Oliveira Almeida VC; Ribeiro DD; Gomes KB; Godard AL
Mol Diagn Ther; 2014 Dec; 18(6):675-83. PubMed ID: 25312789
[TBL] [Abstract][Full Text] [Related]
23. Nutri-pharmacogenomics of warfarin anticoagulation therapy: VKORC1 genotype-dependent influence of dietary vitamin K intake.
Saito R; Takeda K; Yamamoto K; Nakagawa A; Aoki H; Fujibayashi K; Wakasa M; Motoyama A; Iwadare M; Ishida R; Fujioka N; Tsuchiya T; Akao H; Kawai Y; Kitayama M; Kajinami K
J Thromb Thrombolysis; 2014 Jul; 38(1):105-14. PubMed ID: 23928870
[TBL] [Abstract][Full Text] [Related]
24. VKORC1 and CYP2C9 polymorphisms are associated with warfarin dose requirements in Turkish patients.
Oner Ozgon G; Langaee TY; Feng H; Buyru N; Ulutin T; Hatemi AC; Siva A; Saip S; Johnson JA
Eur J Clin Pharmacol; 2008 Sep; 64(9):889-94. PubMed ID: 18542936
[TBL] [Abstract][Full Text] [Related]
25. Non-genetic factors and polymorphisms in genes CYP2C9 and VKORC1: predictive algorithms for TTR in Brazilian patients on warfarin.
Praxedes MFS; Martins MAP; Mourão AOM; Gomes KB; Reis EA; Souza RP; Campos EIF; Ribeiro DD; Rocha MOC
Eur J Clin Pharmacol; 2020 Feb; 76(2):199-209. PubMed ID: 31720756
[TBL] [Abstract][Full Text] [Related]
26. Association between polymorphisms of VKORC1 and CYP2C9 genes with warfarin maintenance dose in a group of warfarin users in Birjand city, Iran.
Fereidouni M; Moossavi M; Kazemi T; Nouranihassankiade S; Asghari A
J Cell Biochem; 2019 Jun; 120(6):9588-9593. PubMed ID: 30525241
[TBL] [Abstract][Full Text] [Related]
27. A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.
Takeuchi F; McGinnis R; Bourgeois S; Barnes C; Eriksson N; Soranzo N; Whittaker P; Ranganath V; Kumanduri V; McLaren W; Holm L; Lindh J; Rane A; Wadelius M; Deloukas P
PLoS Genet; 2009 Mar; 5(3):e1000433. PubMed ID: 19300499
[TBL] [Abstract][Full Text] [Related]
28. Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.
Aquilante CL; Langaee TY; Lopez LM; Yarandi HN; Tromberg JS; Mohuczy D; Gaston KL; Waddell CD; Chirico MJ; Johnson JA
Clin Pharmacol Ther; 2006 Apr; 79(4):291-302. PubMed ID: 16580898
[TBL] [Abstract][Full Text] [Related]
29.
Li D; Zhu H; Luo ZY; Chen Y; Song GB; Zhou XM; Yan H; Zhou HH; Zhang W; Li X
Pharmacogenomics; 2020 Nov; 21(16):1169-1178. PubMed ID: 33094665
[No Abstract] [Full Text] [Related]
30. Linkage disequilibrium between the CYP2C19*2,*17 and CYP2C9*1 alleles and impact of VKORC1, CYP2C9, CYP2C19 gene polymorphisms and gene-gene interactions on warfarin therapy.
Khalighi K; Cheng G; Mirabbasi S; Khalighi B; Wu Y; Fan W
J Thromb Thrombolysis; 2017 Jan; 43(1):124-129. PubMed ID: 27743182
[TBL] [Abstract][Full Text] [Related]
31. Multi-site Investigation of Genetic Determinants of Warfarin Dose Variability in Latinos.
El Rouby N; Rodrigues Marcatto L; Claudio K; Camargo Tavares L; Steiner H; Botton MR; Lubitz SA; Fallon EN; Yee K; Kaye J; Scott SA; Karnes J; Caleb Junior de Lima Santos P; Duconge J; Cavallari LH
Clin Transl Sci; 2021 Jan; 14(1):268-276. PubMed ID: 32860733
[TBL] [Abstract][Full Text] [Related]
32. Genetic Factors Influencing Warfarin Dose in Black-African Patients: A Systematic Review and Meta-Analysis.
Asiimwe IG; Zhang EJ; Osanlou R; Krause A; Dillon C; Suarez-Kurtz G; Zhang H; Perini JA; Renta JY; Duconge J; Cavallari LH; Marcatto LR; Beasly MT; Perera MA; Limdi NA; Santos PCJL; Kimmel SE; Lubitz SA; Scott SA; Kawai VK; Jorgensen AL; Pirmohamed M
Clin Pharmacol Ther; 2020 Jun; 107(6):1420-1433. PubMed ID: 31869433
[TBL] [Abstract][Full Text] [Related]
33. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
[TBL] [Abstract][Full Text] [Related]
34. Genotypes of vitamin K epoxide reductase, gamma-glutamyl carboxylase, and cytochrome P450 2C9 as determinants of daily warfarin dose in Japanese patients.
Kimura R; Miyashita K; Kokubo Y; Akaiwa Y; Otsubo R; Nagatsuka K; Otsuki T; Okayama A; Minematsu K; Naritomi H; Honda S; Tomoike H; Miyata T
Thromb Res; 2007; 120(2):181-6. PubMed ID: 17049586
[TBL] [Abstract][Full Text] [Related]
35. Prevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory Support.
Awad M; Czer LS; Soliman C; Mirocha J; Ruzza A; Pinzas J; Rihbany K; Chang D; Moriguchi J; Ramzy D; Esmailian F; Kobashigawa J; Arabia F
ASAIO J; 2015; 61(4):391-6. PubMed ID: 26125664
[TBL] [Abstract][Full Text] [Related]
36. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
37. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
38. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
[TBL] [Abstract][Full Text] [Related]
39. A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients.
Chen J; Shao L; Gong L; Luo F; Wang J; Shi Y; Tan Y; Chen Q; Zhang Y; Hui R; Wang Y
PLoS One; 2014; 9(8):e105250. PubMed ID: 25126975
[TBL] [Abstract][Full Text] [Related]
40. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
